ReviewCurrent oncology reports2020
Hairy Cell Leukaemia.
Review in Current oncology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Article
- Successful treatment of hairy cell leukaemia with pegylated interferon-alpha-2A.Pathology oncology research : POR · 2025Article
- Pseudomonocytosis on a Sysmex XN haematology analyser masking the monocytopenia of hairy cell leukaemia in a South African woman.African journal of laboratory medicine · 2025Article
- [The value of CD200 in differential diagnosis of classic hairy cell leukemia and variant hairy cell leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- Flow Cytometry of CD5-Positive Hairy Cell Leukemia.Molecular diagnosis & therapy · 2023Article
- Article
- Atraumatic Splenic Rupture as an Unusual Presentation of Hairy Cell Leukemia: A Case Report.Cureus · 2023Article
- Almost a Near Miss: Hairy Cell Leukemia.Cureus · 2023Article
- Review
- Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study.Blood advances · 2022Article
- Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia.Hematological oncology · 2022Article
- Review
- Advances in the Treatment of Hairy Cell Leukemia Variant.Current treatment options in oncology · 2022Review
- Case Report: Development of Diffuse Large B Cell Lymphoma a Long Time After Hairy Cell Leukemia.Pathology oncology research : POR · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo summarise diagnostic clinical/laboratory findings and highlight differences between classical hairy cell leukaemia (HCLc) and hairy cell leukaemia variant (HCLv). Discussion of prognosis and current treatment indications including novel therapies, linked to understanding of the underlying molecular pathogenesis. RECENT
findingsImproved understanding of the underlying pathogenesis of HCLc, particularly the causative mutation BRAF V600E, leading to constitutive activation of the MEK/ERK signalling pathway and increased cell proliferation. HCLc is caused by BRAF V600E mutation in most cases. Purine nucleoside analogue (PNA) therapy is the mainstay of treatment, with the addition of rituximab, improving response and minimal residual disease (MRD) clearance. Despite excellent responses to PNAs, many patients will eventually relapse, requiring further therapy. Rarely, patients are refractory to PNA therapy. In relapsed/refractory patients, novel targeted therapies include BRAF inhibitors (BRAFi), anti-CD22 immunoconjugate moxetumomab and Bruton tyrosine kinase inhibitors (BTKi). HCLv has a worse prognosis with median overall survival (OS), only 7-9 years, despite the combination of PNA/rituximab improving front-line response. Moxetumomab or ibrutinib may be a viable treatment but lacks substantial evidence.
Indexed as
Identifiers
32297104What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.